Piramal Pharma Q1 FY27 Result: Revenue Climbs 17% Even As Company Reports ₹69 Crore Loss

Piramal Pharma reported broad-based revenue growth across its businesses in the June quarter. Consolidated revenue from operations stood at ₹2,270 crore, up from ₹1,934 crore a year ago, while earnings before interest, taxes, depreciation, and amortisation (EBITDA) climbed to ₹285 crore from ₹165 crore. The company reported a consolidated net loss of ₹69 crore after exceptional items, compared with a loss of ₹82 crore in the corresponding quarter last year.

Revenue growth came from all three business segments: Contract Development and Manufacturing Organisation (CDMO), Complex Hospital Generics (CHG), and Consumer Healthcare (PCH).

Piramal Pharma Results: How Did The Company Perform In Q1?

Revenue from operations increased 17% year-on-year to ₹2,270 crore during the June quarter. EBITDA rose 72% to ₹285 crore, taking the EBITDA margin to 12.5%, compared with 8.5% a year earlier. The improvement reflected stronger operating performance across businesses.

Piramal Pharma reported a smaller quarterly loss, with the June-quarter deficit narrowing to ₹69 crore from ₹82 crore a year ago. Before exceptional items, the loss stood at ₹69 crore, compared with ₹102 crore in Q1 FY26.

All three businesses contributed to revenue growth during the quarter. CDMO generated ₹1,187 crore, followed by CHG at ₹743 crore and PCH at ₹347 crore. Year-on-year growth stood at 19%, 17% and 15%, respectively.

On 29 July, Piramal Pharma shares closed at ₹195.68 on the National Stock Exchange, up 1.16% for the day.

What Supported Piramal Pharma Financials In Q1 FY27?

The CDMO business benefited from higher request-for-proposal activity, improved order inflows across multiple manufacturing sites and stronger commercial execution. The company also pointed to favourable industry trends, including higher biopharma funding and supply-chain diversification, which supported customer demand. It said profitability improved across both Indian and overseas facilities through better capacity utilisation, pricing discipline and operational measures.

In the CHG business, Piramal Pharma maintained its leadership position in the US sevoflurane and intrathecal baclofen markets. Sales of inhalation anaesthesia products outside the US picked up during the quarter. The company also said that supplies of the acquired Kenalog portfolio are expected to begin in Q2 FY27, while it continues to invest in differentiated hospital products and specialty medicines.

PCH maintained double-digit growth, led by its power brands and online sales. Power brands recorded 23% year-on-year growth and accounted for 53% of segment revenue. E-commerce sales grew 40% and contributed 28% of Consumer Healthcare revenue.

The company continued investing in brand promotion, expanded distribution across multiple channels and took selective price increases alongside cost-control measures to offset raw material inflation.

Piramal Pharma Management's Outlook

Chairperson Nandini Piramal said the company began FY27 on a strong footing, with all three businesses delivering healthy revenue growth alongside better EBITDA margins. Management said it expects to build on this performance through the rest of the financial year, supported by continued execution across the CDMO business, expanding traction in hospital generics and sustained growth in consumer healthcare.

Also Read - Stocks To Watch On 30 July 2026: Bajaj Housing Finance, Dabur India, Redington And More